# Anaptysbio, Inc: financial statements, quarterly

ANAB · Nasdaq · CIK 1370053 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/anab.md) · [Financials](/companies/anab/financials.md) · [Filings](/companies/anab/filings.md) · [Insiders](/companies/anab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.3](/filings/0001370053-24-000054.md) | [9.0 d](/filings/0001193125-26-088290.md) | [7.2](/filings/0001370053-25-000046.md) | [11.0](/filings/0001370053-25-000064.md) | [30.0](/filings/0001370053-25-000089.md) | [43.1 d](/filings/0001193125-26-396696.md) | [27.8](/filings/0001193125-26-219515.md) | [22.3](/filings/0001370053-25-000064.md) | [76.3](/filings/0001370053-25-000089.md) | [108 d](/filings/0001193125-26-396696.md) | [25.6](/filings/0001193125-26-219515.md) | [27.5 d](/filings/0001193125-26-396696.md) |
| Research and development | $m | [30.9](/filings/0001370053-24-000054.md) | not reported | [37.0](/filings/0001370053-25-000046.md) | [42.0](/filings/0001370053-25-000064.md) | [42.2](/filings/0001370053-25-000089.md) | not reported | [41.2](/filings/0001370053-25-000046.md) | [37.8](/filings/0001370053-25-000064.md) | [31.4](/filings/0001370053-25-000089.md) | not reported | not reported | not reported |
| Operating income | $m | [(37.7)](/filings/0001370053-24-000054.md) | [(42.1) d](/filings/0001193125-26-088290.md) | [(42.2)](/filings/0001370053-25-000046.md) | [(40.3)](/filings/0001370053-25-000064.md) | [(22.8)](/filings/0001370053-25-000089.md) | [171 d](/filings/0001193125-26-396696.md) | [(27.5)](/filings/0001193125-26-219515.md) | [(26.2)](/filings/0001370053-25-000064.md) | [34.7](/filings/0001370053-25-000089.md) | [246 d](/filings/0001193125-26-396696.md) | [(34.6)](/filings/0001193125-26-219515.md) | [67.0 d](/filings/0001193125-26-396696.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001370053-24-000054.md) | [(0.0) d](/filings/0001193125-26-088290.md) | [0.0](/filings/0001370053-25-000046.md) | [0.0](/filings/0001370053-25-000064.md) | [0.0](/filings/0001370053-25-000089.md) | [0.1 d](/filings/0001193125-26-396696.md) | [0.0](/filings/0001193125-26-219515.md) | [0.0](/filings/0001370053-25-000064.md) | [0.0](/filings/0001370053-25-000089.md) | [0.7 d](/filings/0001193125-26-396696.md) | [0.0](/filings/0001193125-26-219515.md) | [(181) d](/filings/0001193125-26-396696.md) |
| Net income | $m | [(37.3)](/filings/0001370053-24-000054.md) | [(42.2) d](/filings/0001193125-26-187044.md) | [(43.9)](/filings/0001370053-25-000089.md) | [(46.7)](/filings/0001370053-25-000089.md) | [(32.9)](/filings/0001370053-25-000089.md) | [(21.8) d](/filings/0001193125-26-396696.md) | [(39.3)](/filings/0001193125-26-219515.md) | [(38.6)](/filings/0001370053-25-000089.md) | [15.1](/filings/0001370053-25-000089.md) | [49.6 d](/filings/0001193125-26-396696.md) | [(52.9)](/filings/0001193125-26-219515.md) | [184 d](/filings/0001193125-26-396696.md) |
| Diluted EPS | $ per share | [(1.41)](/filings/0001370053-24-000054.md) | not reported | [(1.64)](/filings/0001370053-25-000046.md) | [(1.71)](/filings/0001370053-25-000064.md) | [(1.14)](/filings/0001370053-25-000089.md) | not reported | [(1.28)](/filings/0001193125-26-219515.md) | [(1.34)](/filings/0001370053-25-000064.md) | [0.52](/filings/0001370053-25-000089.md) | not reported | [(1.84)](/filings/0001193125-26-219515.md) | not reported |
| Basic EPS | $ per share | [(1.41)](/filings/0001370053-24-000054.md) | not reported | [(1.64)](/filings/0001370053-25-000046.md) | [(1.71)](/filings/0001370053-25-000064.md) | [(1.14)](/filings/0001370053-25-000089.md) | not reported | [(1.28)](/filings/0001193125-26-219515.md) | [(1.34)](/filings/0001370053-25-000064.md) | [0.54](/filings/0001370053-25-000089.md) | not reported | [(1.84)](/filings/0001193125-26-219515.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.3](/filings/0001370053-23-000065.md) | [36.0](/filings/0001370053-25-000024.md) | [53.7](/filings/0001370053-24-000027.md) | [71.8](/filings/0001370053-24-000041.md) | [192](/filings/0001370053-24-000054.md) | [23.1](/filings/0001193125-26-396696.md) | [98.6](/filings/0001370053-25-000046.md) | [44.3](/filings/0001370053-25-000064.md) | [110](/filings/0001370053-25-000089.md) | [138](/filings/0001193125-26-396696.md) | [248](/filings/0001193125-26-219515.md) | [134](/filings/0001193125-26-396696.md) |
| Current assets | $m | [428](/filings/0001370053-23-000065.md) | [407](/filings/0001370053-25-000024.md) | [372](/filings/0001370053-24-000027.md) | [367](/filings/0001370053-24-000041.md) | [449](/filings/0001370053-24-000054.md) | [432](/filings/0001193125-26-396696.md) | [363](/filings/0001370053-25-000046.md) | [292](/filings/0001370053-25-000064.md) | [331](/filings/0001370053-25-000089.md) | [350](/filings/0001193125-26-396696.md) | [316](/filings/0001193125-26-219515.md) | [198](/filings/0001193125-26-396696.md) |
| Total assets | $m | [487](/filings/0001370053-23-000065.md) | [452](/filings/0001370053-25-000024.md) | [406](/filings/0001370053-24-000027.md) | [427](/filings/0001370053-24-000041.md) | [493](/filings/0001370053-24-000054.md) | [484](/filings/0001193125-26-396696.md) | [422](/filings/0001370053-25-000046.md) | [335](/filings/0001370053-25-000064.md) | [353](/filings/0001370053-25-000089.md) | [364](/filings/0001193125-26-396696.md) | [330](/filings/0001193125-26-219515.md) | [317](/filings/0001193125-26-396696.md) |
| Current liabilities | $m | [39.2](/filings/0001370053-23-000065.md) | [37.4](/filings/0001370053-25-000024.md) | [32.3](/filings/0001370053-24-000027.md) | [40.4](/filings/0001370053-24-000041.md) | [43.9](/filings/0001370053-24-000054.md) | [45.4](/filings/0001193125-26-396696.md) | [44.0](/filings/0001370053-25-000046.md) | [35.5](/filings/0001370053-25-000064.md) | [38.1](/filings/0001370053-25-000089.md) | [38.6](/filings/0001193125-26-396696.md) | [41.7](/filings/0001193125-26-219515.md) | [35.4](/filings/0001193125-26-396696.md) |
| Shareholders' equity | $m | [120](/filings/0001370053-24-000054.md) | [88.1](/filings/0001193125-26-396696.md) | [47.8](/filings/0001370053-25-000089.md) | [9.9](/filings/0001370053-25-000089.md) | [84.4](/filings/0001370053-25-000089.md) | [70.9](/filings/0001193125-26-396696.md) | [34.0](/filings/0001193125-26-219515.md) | [(44.7)](/filings/0001370053-25-000089.md) | [(29.4)](/filings/0001370053-25-000089.md) | [37.2](/filings/0001193125-26-396696.md) | [12.7](/filings/0001193125-26-219515.md) | [10.6](/filings/0001193125-26-396696.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(36.5) d](/filings/0001370053-24-000054.md) | [(34.3) d](/filings/0001193125-26-088290.md) | [(37.3)](/filings/0001370053-25-000046.md) | [(21.3) d](/filings/0001370053-25-000064.md) | [(10.1) d](/filings/0001370053-25-000089.md) | [(66.7) d](/filings/0001193125-26-396696.md) | [(10.7)](/filings/0001193125-26-219515.md) | [(40.2) d](/filings/0001193125-26-396696.md) | [(27.4) d](/filings/0001370053-25-000089.md) | [98.0 d](/filings/0001193125-26-396696.md) | [(25.9)](/filings/0001193125-26-219515.md) | [(26.6) d](/filings/0001193125-26-396696.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001370053-24-000054.md) | [0.3 d](/filings/0001193125-26-088290.md) | [0.0](/filings/0001370053-25-000046.md) | [0.0 d](/filings/0001370053-25-000064.md) | [0.0 d](/filings/0001370053-25-000089.md) | [0.3 d](/filings/0001193125-26-088290.md) | [0.0](/filings/0001193125-26-219515.md) | [0.0 d](/filings/0001370053-25-000064.md) | [0.0 d](/filings/0001370053-25-000089.md) | [0.0 d](/filings/0001193125-26-088290.md) | [0.0](/filings/0001193125-26-219515.md) | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001370053-24-000054.md) | [0.0 d](/filings/0001193125-26-088290.md) | [0.0](/filings/0001370053-25-000046.md) | [0.0 d](/filings/0001370053-25-000064.md) | [0.0 d](/filings/0001370053-25-000089.md) | [0.5 d](/filings/0001193125-26-396696.md) | [4.4](/filings/0001193125-26-219515.md) | [51.1 d](/filings/0001193125-26-396696.md) | [9.7 d](/filings/0001370053-25-000089.md) | [3.4 d](/filings/0001193125-26-396696.md) | [0.0](/filings/0001193125-26-219515.md) | [0.0 d](/filings/0001193125-26-396696.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.2](/filings/0001370053-23-000049.md) | [28.3](/filings/0001370053-23-000065.md) | [28.0](/filings/0001370053-24-000027.md) | [26.6](/filings/0001370053-24-000041.md) | [26.5](/filings/0001370053-24-000054.md) | [26.8](/filings/0001370053-25-000046.md) | [27.4](/filings/0001370053-25-000064.md) | [28.9](/filings/0001370053-25-000089.md) | [30.6](/filings/0001193125-26-219515.md) | [28.8](/filings/0001370053-25-000064.md) | [29.0](/filings/0001370053-25-000089.md) | [28.7](/filings/0001193125-26-219515.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,895,244 at 2026-09-16, from the cover of the [10-KT filed 2026-09-21](/filings/0001193125-26-396696.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.